Nucleic Acids For Apoptosis Of Cancer Cells

• US 20080045471A1
• Filed: 03/27/2007
• Published: 02/21/2008
• Est. Priority Date: 03/27/2006
• Status: Abandoned Application

• Current Assignee: Sky Genetics, Inc.
• Original Assignee: Sky Genetics, Inc.
• Inventors: North, Don
• Application Number:
  US11/691,994
• Publication Number:
  US 20080045471A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/31 of the backbone

Abstract

The disclosure relates to nucleic acids having Apoptotic Sequence Nos. 5, 8, 9, 11, 14, 60 and 66. It also relates to agents targeting Apoptotic Sequences, said agents having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, and SEQ ID NO:7. The composition may also include a pharmaceutically acceptable carrier. The disclosure also includes a method of killing a cancer cell by administering to a cancer cell a treatment formulation including a nucleic acid having an Apoptotic Sequence targeting agent of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, and SEQ ID NO:7 and a pharmaceutically acceptable carrier. The cancer cell may be located in a subject with cancer.

Claims

1. A targeting agent comprising a first isolated nucleic acid molecule that specifically hybridizes to a second nucleic acid having an Apoptotic Sequence and located in a cancer cell, wherein delivery of the targeting agent into the cancer cell results in induction of cell death in the cancer cell.

2. The targeting agent of claim 1, wherein the first isolated nucleic acid comprises a DNA molecule.

3. The targeting agent of claim 1, wherein the first isolated nucleic acid comprises an RNA molecule.

4. The targeting agent of claim 1, wherein the second nucleic acid comprises a DNA molecule.

5. The targeting agent of claim 1, wherein the second nucleic acid comprises a RNA molecule.

6. The targeting agent of claim 1, wherein the first isolated nucleic acid comprises inter-nucleotide linkages other than phosphodiester bonds.

7. The targeting agent of claim 6, wherein the inter-nucleotide linkages comprise a phosphorothioate, a methylphosphonate, a methylphosphodiester, a phosphorodithioate, a phosphoramidate, a phosphotriester, or a phosphate ester linkage.

8. The targeting agent of claim 1, wherein the first isolated nucleic acid molecule specifically hybridizes to second nucleic acid molecule comprising a sequence selected from the group consisting of:

SEQ.ID.NO;

1, SEQ.ID.NO;

2, SEQ.ID.NO;

3, SEQ.ID.NO;

4, SEQ.ID.NO;

5, SEQ.ID.NO;

6, SEQ.ID.NO;

7, and sequences complementary thereto.

9. A composition comprising:

a first isolated nucleic acid molecule that specifically hybridizes to a second nucleic acid having an Apoptotic Sequence and located in a cancer cell; and

a pharmaceutically acceptable carrier,

wherein delivery of the targeting agent into the cancer cell results in induction of cell death in the cancer cell.

10. The targeting agent of claim 9, wherein the first isolated nucleic acid molecule specifically hybridizes to second nucleic acid molecule comprising a sequence selected from the group consisting of:

SEQ.ID.NO;

1, SEQ.ID.NO;

2, SEQ.ID.NO;

3, SEQ.ID.NO;

4, SEQ.ID.NO;

5, SEQ.ID.NO;

6, SEQ.ID.NO;

7, and sequences complementary thereto.

11. The targeting agent of claim 9, further comprising a coating to protect the first isolated nucleic acid from the action of alkali, acid and other natural conditions that may cause degradation of the nucleic acid.

12. A method of killing a cancer cell comprising:

administering to the cancer cell a first isolated nucleic acid molecule that specifically hybridizes to a second nucleic acid having an Apoptotic Sequence and located in the cancer cell; and

inducing cell death in the cancer cell via the first isolated nucleic acid.

13. The method of claim 12, wherein the first isolated nucleic acid molecule specifically hybridizes to second nucleic acid molecule comprising a sequence selected from the group consisting of:

SEQ.ID.NO;

1, SEQ.ID.NO;

2, SEQ.ID.NO;

3, SEQ.ID.NO;

4, SEQ.ID.NO;

5, SEQ.ID.NO;

6, SEQ.ID.NO;

7, and sequences complementary thereto.

14. The method of claim 12, wherein cancer cell death comprises apoptosis.

15. The method of claim 12, comprising administering the first isolated nucleic acid to the cancer cell in a subject with cancer.

16. The method of claim 15, wherein the cancer cell is a breast cancer.

17. The method of claim 15, wherein the cancer cell is a a colon cancer.

18. The method of claim 15, wherein the cancer cell is a lung cancer.

19. The method of claim 15, wherein the cancer cell is a brain cancer.

20. The method of claim 15, wherein the cancer cell is a glioblastoma.

21. The method of claim 15, wherein the cancer cell is a medulloblastoma.

22. The method of claim 15, wherein the cancer cell is an ovarian cancer.

23. The method of claim 15, comprising administering the first isolated nucleic acid in a pharmaceutically acceptable carrier.